1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Hartgrink HH, Jansen EP, van Grieken NC
and van de Velde CJ: Gastric cancer. Lancet. 374:477–490. 2009.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Zabaleta J: Multifactorial etiology of
gastric cancer. Methods Mol Biol. 863:411–435. 2012. View Article : Google Scholar : PubMed/NCBI
|
4
|
Su JM, Lin P, Wang CK and Chang H:
Overexpression of cytochrome P450 1B1 in advanced non-small cell
lung cancer: A potential therapeutic target. Anticancer Res.
29:509–515. 2009.PubMed/NCBI
|
5
|
Schlezinger JJ, Liu D, Farago M, Seldin
DC, Belguise K, Sonenshein GE and Sherr DH: A role for the aryl
hydrocarbon receptor in mammary gland tumorigenesis. Biol Chem.
387:1175–1187. 2006. View Article : Google Scholar : PubMed/NCBI
|
6
|
Fritz WA, Lin TM, Safe S, Moore RW and
Peterson RE: The selective aryl hydrocarbon receptor modulator
6-methyl-1,3,8-trichlorodibenzofuran inhibits prostate tumor
metastasis in TRAMP mice. Biochem Pharmacol. 77:1151–1160. 2009.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Yin XF, Chen J, Mao W, Wang YH and Chen
MH: A selective aryl hydrocarbon receptor modulator
3,3′-diindolylmethane inhibits gastric cancer cell growth. J Exp
Clin Cancer Res. 31:462012. View Article : Google Scholar : PubMed/NCBI
|
8
|
Chen J, Röcken C, Klein-Hitpass L, Götze
T, Leodolter A, Malfertheiner P and Ebert MP: Microarray analysis
of gene expression in metastatic gastric cancer cells after
incubation with the methylation inhibitor 5-aza-2′-deoxycytidine.
Clin Exp Metastasis. 21:389–397. 2004. View Article : Google Scholar : PubMed/NCBI
|
9
|
Peng TL, Chen J, Mao W, Liu X, Tao Y, Chen
LZ and Chen MH: Potential therapeutic significance of increased
expression of aryl hydrocarbon receptor in human gastric cancer.
World J Gastroenterol. 15:1719–1729. 2009. View Article : Google Scholar : PubMed/NCBI
|
10
|
Yin XF, Chen J, Mao W, Wang YH and Chen
MH: A selective aryl hydrocarbon receptor modulator
3,3′-diindolylmethane inhibits gastric cancer cell growth. J Exp
Clin Cancer Res. 31:462012. View Article : Google Scholar : PubMed/NCBI
|
11
|
Chang YC, Riby J, Chang GH, Peng BC,
Firestone G and Bjeldanes LF: Cytostatic and antiestrogenic effects
of 2-(indol-3-ylmethyl)-3,3′-diindolylmethane, a major in vivo
product of dietary indole-3-carbinol. Biochem Pharmacol.
58:825–834. 1999. View Article : Google Scholar : PubMed/NCBI
|
12
|
Loganathan S, Kandala PK, Gupta P and
Srivastava SK: Inhibition of EGFR-AKT axis results in the
suppression of ovarian tumors in vitro and in preclinical mouse
model. PLoS One. 7:e435772012. View Article : Google Scholar : PubMed/NCBI
|
13
|
Chen D, Banerjee S, Cui QC, Kong D, Sarkar
FH and Dou QP: Activation of AMP-activated protein kinase by
3,3′-diindolylmethane (DIM) is associated with human prostate
cancer cell death in vitro and in vivo. PLoS One. 7:e471862012.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Pappa G, Strathmann J, Löwinger M, Bartsch
H and Gerhäuser C: Quantitative combination effects between
sulforaphane and 3,3′-diindolylmethane on proliferation of human
colon cancer cells in vitro. Carcinogenesis. 28:1471–1477. 2007.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Ali S, Banerjee S, Schaffert JM, El-Rayes
BF, Philip PA and Sarkar FH: Concurrent inhibition of NF-kappaB,
cyclooxygenase-2, and epidermal growth factor receptor leads to
greater anti-tumor activity in pancreatic cancer. J Cell Biochem.
110:171–181. 2010.PubMed/NCBI
|
16
|
Choi HJ, Lim DY and Park JH: Induction of
G1 and G2/M cell cycle arrests by the dietary compound
3,3′-diindolylmethane in HT-29 human colon cancer cells. BMC
Gastroenterol. 9:392009. View Article : Google Scholar : PubMed/NCBI
|
17
|
Tadi K, Chang Y, Ashok BT, Chen Y,
Moscatello A, Schaefer SD, Schantz SP, Policastro AJ, Geliebter J
and Tiwari RK: 3,3′-Diindolylmethane, a cruciferous vegetable
derived synthetic anti-proliferative compound in thyroid disease.
Biochem Biophys Res Commun. 337:1019–1025. 2005. View Article : Google Scholar : PubMed/NCBI
|
18
|
Chang X, Firestone GL and Bjeldanes LF:
Inhibition of growth factor-induced Ras signaling in vascular
endothelial cells and angiogenesis by 3,3′-diindolylmethane.
Carcinogenesis. 27:541–550. 2006. View Article : Google Scholar : PubMed/NCBI
|
19
|
Kim EJ, Shin M, Park H, Hong JE, Shin HK,
Kim J, Kwon DY and Park JH: Oral administration of
3,3′-diindolylmethane inhibits lung metastasis of 4T1 murine
mammary carcinoma cells in BALB/c mice. J Nutr. 139:2373–2379.
2009. View Article : Google Scholar : PubMed/NCBI
|
20
|
Ahmad A, Kong D, Wang Z, Sarkar SH,
Banerjee S and Sarkar FH: Down-regulation of uPA and uPAR by
3,3′-diindolylmethane contributes to the inhibition of cell growth
and migration of breast cancer cells. J Cell Biochem. 108:916–925.
2009. View Article : Google Scholar : PubMed/NCBI
|
21
|
Banerjee S, Wang Z, Kong D and Sarkar FH:
3,3′-Diindolylmethane enhances chemosensitivity of multiple
chemotherapeutic agents in pancreatic cancer. Cancer Res.
69:5592–5600. 2009. View Article : Google Scholar : PubMed/NCBI
|
22
|
Ali S, Banerjee S, Ahmad A, El-Rayes BF,
Philip PA and Sarkar FH: Apoptosis-inducing effect of erlotinib is
potentiated by 3,3′-diindolylmethane in vitro and in vivo using an
orthotopic model of pancreatic cancer. Mol Cancer Ther.
7:1708–1719. 2008. View Article : Google Scholar : PubMed/NCBI
|
23
|
Fares F, Azzam N, Appel B, Fares B and
Stein A: The potential efficacy of 3,3′-diindolylmethane in
prevention of prostate cancer development. Eur J Cancer Prev.
19:199–203. 2010. View Article : Google Scholar : PubMed/NCBI
|
24
|
Kong D, Li Y, Wang Z, Banerjee S and
Sarkar FH: Inhibition of angiogenesis and invasion by
3,3′-diindolylmethane is mediated by the nuclear factor-kappaB
downstream target genes MMP-9 and uPA that regulated
bioavailability of vascular endothelial growth factor in prostate
cancer. Cancer Res. 67:3310–3319. 2007. View Article : Google Scholar : PubMed/NCBI
|
25
|
Jin Y: 3,3′-Diindolylmethane inhibits
breast cancer cell growth via miR-21-mediated Cdc25A degradation.
Mol Cell Biochem. 358:345–354. 2011. View Article : Google Scholar : PubMed/NCBI
|
26
|
Mimura J, Yamashita K, Nakamura K, Morita
M, Takagi TN, Nakao K, Ema M, Sogawa K, Yasuda M, Katsuki M and
Fujii-Kuriyama Y: Loss of teratogenic response to
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in mice lacking the Ah
(dioxin) receptor. Genes Cells. 2:645–654. 1997. View Article : Google Scholar : PubMed/NCBI
|
27
|
Ichite N, Chougule MB, Jackson T, Fulzele
SV, Safe S and Singh M: Enhancement of docetaxel anticancer
activity by a novel diindolylmethane compound in human non-small
cell lung cancer. Clin Cancer Res. 15:543–552. 2009. View Article : Google Scholar : PubMed/NCBI
|
28
|
Li Y, Chinni SR and Sarkar FH: Selective
growth regulatory and pro-apoptotic effects of DIM is mediated by
AKT and NF-kappaB pathways in prostate cancer cells. Front Biosci.
10:236–243. 2005. View
Article : Google Scholar : PubMed/NCBI
|
29
|
Xu Y, Zhang J, Shi W and Liu Y: Anticancer
effects of 3,3′-diindolylmethane are associated with G1 arrest and
mitochondria-dependent apoptosis in human nasopharyngeal carcinoma
cells. Oncol Lett. 5:655–662. 2013.PubMed/NCBI
|
30
|
Roh YS, Cho A, Islam MR, Cho SD, Kim J,
Kim JH, Lee JW, Lim CW and Kim B: 3,3′-Diindolylmethane induces
immunotoxicity via splenocyte apoptosis in neonatal mice. Toxicol
Lett. 206:218–228. 2011. View Article : Google Scholar : PubMed/NCBI
|
31
|
Anderton MJ, Manson MM, Verschoyle R,
Gescher A, Steward WP, Williams ML and Mager DE: Physiological
modeling of formulated and crystalline 3,3′-diindolylmethane
pharmacokinetics following oral administration in mice. Drug Metab
Dispos. 32:632–638. 2004. View Article : Google Scholar : PubMed/NCBI
|